100% agree with you, mate. Imagine not selling when IMU was >20c. He's definitely showcasing his intelligence in that regard. He's probably giving IMU a second moments thought because he's a shareholder of Vaxinia PTY LTD and is about to receive a portion of 150M shares for successful P1 safety endpoints.
Interviews are great when you are getting paid, but great interviews don't fix a DRR of 2.5% (1/40) for CF33. It's clear now that the 2 PRs were not durable, therefore those patients have progressed. If they haven't, why comment on cholangiocarcinoma patient duration and not melanoma patients? Once again, I am the only one paying attention to the details.
@Steini have you seriously only just worked out HER2 is crowded? LOL. It was crowded in 2017 when HER-Vaxx started. My god, man.
